Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
THERAPEUTIC MEDICINE FOR FIBROUS DISEASE
Document Type and Number:
WIPO Patent Application WO/2018/186480
Kind Code:
A1
Abstract:
The inventors of the present invention found that an HMGB1 peptide fragment having a specific amino acid sequence is effective at suppressing finger fusion and scarring of the digestive tract, and at prolonging survival in malnutrition- type epidermolysis bullosa model mice. The inventors also found that in a cutaneous ulcer model, administration of the specific HMGB1 peptide fragment suppresses the fibrosing of skin that occurs in the healing process of the ulcer. The present invention, on the basis of these findings, provides a pharmaceutical composition for fibrous disease treatment, which contains the specific HMGB1 peptide fragment.

Inventors:
TAMAI, Katsuto (1-1 Yamadaoka, Suita-sh, Osaka 71, 〒5650871, JP)
AOTO, Takahiro (3FL, Saito Biotechnology Incubator, 7-15, Saito-Asagi 7-chome, Ibaraki-sh, Osaka 85, 〒5670085, JP)
YAMAZAKI, Sho (3FL, Saito Biotechnology Incubator, 7-15, Saito-Asagi 7-chome, Ibaraki-sh, Osaka 85, 〒5670085, JP)
YAMAZAKI, Takehiko (3FL, Saito Biotechnology Incubator, 7-15, Saito-Asagi 7-chome, Ibaraki-sh, Osaka 85, 〒5670085, JP)
Application Number:
JP2018/014662
Publication Date:
October 11, 2018
Filing Date:
April 06, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
STEMRIM INC. (3FL Saito Biotechnology Incubator, 7-15 Saito-Asagi 7-chome, Ibaraki-sh, Osaka 85, 〒5670085, JP)
OSAKA UNIVERSITY (1-1 Yamadaoka, Suita-shi Osaka, 71, 〒5650871, JP)
International Classes:
A61K38/16; A61P1/00; A61P1/16; A61P1/18; A61P9/00; A61P11/00; A61P13/12; A61P15/00; A61P17/00; A61P17/02; A61P19/00; A61P19/02; A61P19/04; A61P21/00; A61P27/02
Domestic Patent References:
WO2012147470A12012-11-01
WO2011052668A12011-05-05
WO2012147470A12012-11-01
WO2014065347A12014-05-01
Other References:
TAMAI, KATSUTO: "Development on regenerative-inducing medicine using regeneration mechanism of damaged body tissues with respect to peripheral circulation mesenchymal cells", 6. DEVELOPMENT ON REGENERATIVE-INDUCING MEDICINE USING MOBILIZING ACTIVITY IN BLOOD OF BONE MARROW PDGFRA-POSITIVE CELLS OF HMGB1, vol. 31, 10 September 2016 (2016-09-10), pages 1045 - 1046, ISSN: 0919-8237
KOSHIBA, YUKI: "Effectiveness of mesenchymal stem cell mobilization by administration of HMGBl with respect to bleomycin-induced skin fibrosis", 48TH ANNUAL MEETING OF THE JAPANESE SOCIETY FOR MATRIX BIOLOGY AND MEDICINE; 24-25/06/2016, vol. 48th, 2016, pages 78, XP009516429
KIKUCHI, YASUSHI ET AL.: "P-02-112: Systemic administration of HMGB1 improves bleomycin-induced skin fibrosis by locally concentrating bone marrow mesenchymal stem cells", REGENERATIVE MEDICINE, vol. 16, 1 February 2017 (2017-02-01), pages 422, XP009516430, ISSN: 1347-7919
KANEDA , YASUSHI ET AL.: "Tissue restoration mechanism by bone marrow-derived mesenchymal stem cells", 3. SKIN REGENERATION BY ADMINISTRATION OF HMGB1, vol. 31, no. 5, 2013, pages 655 - 661, ISSN: 0288-5514
GOTO, TAKAZUMI ET AL., REVIEW ON EFFECTIVENESS OF MYOCARDIUM REGENERATIVE-INDUCING THERAPY USING HMGB1 WITH RESPECT TO MYOCARDIAL INFARCTION, vol. 16, 1 February 2017 (2017-02-01), pages 289, ISSN: 1347-7919
FRITSCH ET AL., J CLIN INVEST., vol. 118, no. 5, May 2008 (2008-05-01), pages 1669 - 79
"Remington's Pharmaceutical Science", MARK PUBLISHING COMPANY
Attorney, Agent or Firm:
HARUNA, Masao et al. (Kantetsu Tsukuba Bldg. 6F, 1-1-1 Oroshi-machi, Tsuchiura-sh, Ibaraki 47, 〒3000847, JP)
Download PDF: